• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

6.900 -0.250 (-3.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 584,227
Open 7.910
Bid (Size) 6.720 (600)
Ask (Size) 7.000 (100)
Prev. Close 7.150
Today's Range 6.650 - 7.990
52wk Range 1.900 - 34.80
Shares Outstanding 620,290
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Blocking Fructose Metabolism Boosts Immune Response to Childhood Cancer
Today 10:05 EDT
Via Investor Brand Network
Immunologists Discover How Cancer Reprograms Immune Cells to Support Cancer Growth
May 05, 2026
Via Investor Brand Network

Performance

YTD
+30.2%
+30.2%
1 Month
+197.4%
+197.4%
3 Month
+32.4%
+32.4%
6 Month
+1.1%
+1.1%
1 Year
-47.7%
-47.7%

More News

Read More
Wondering what's happening in today's pre-market session? ↗
May 05, 2026
Via Chartmill
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures $22.5 Million Private Placement Financing
May 04, 2026
Via Investor Brand Network
News headline image
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
May 04, 2026
Via ACCESS Newswire
Study Finds Exercise, Ibuprofen Combat Brain Fog in Cancer Patients
April 28, 2026
Via Investor Brand Network
New Molecule May Open New Therapeutic Pathway Against Brain Cancer
April 27, 2026
Via Investor Brand Network
Why Molecular Testing is Increasingly Important in CNS Cancers
April 21, 2026
Via Investor Brand Network
Scientists Discover Brain Cells That Aid Brain Cancer Development
April 15, 2026
Via Investor Brand Network
Preclinical Study Reveals Promising Treatment for Glioblastoma
April 14, 2026
Via Investor Brand Network
Study Explores Whether a Common Vitamin Could Fight Brain Cancer
April 07, 2026
Via Investor Brand Network
Researchers Solve 50-Year-Old Challenge in Making Cancer Drug
April 01, 2026
Via Investor Brand Network
Researchers Discover Mechanism Behind Deadly Pediatric Brain Cancer
March 31, 2026
Via Investor Brand Network
Misinformation Could Thwart the Potential of Cancer Vaccines
March 24, 2026
Via Investor Brand Network
Fewer Men Undergo Cancer Screening, Study Shows
March 23, 2026
Via Investor Brand Network
Mirror-Image Amino Acid Shows Promise in Starving Cancer Cells
March 17, 2026
Via Investor Brand Network
Researchers Trace Differing Pediatric Brain Tumors to Common Source
March 11, 2026
Via Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology And Oncology Pipeline Expansion
March 11, 2026
Via Investor Brand Network
News headline image
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
March 11, 2026
Via ACCESS Newswire
New Research Challenges Current Thinking on How Brain Cancer Develops
March 10, 2026
Via Investor Brand Network
New Treatment Dramatically Improves Survival for Patients with Deadly Brain Tumors
March 03, 2026
Via Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer
March 02, 2026
Via Investor Brand Network
New Study Unveils Promising Way to Conduct Brain Surgery Against Cancer
March 02, 2026
Via Investor Brand Network
News headline image
CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team
March 02, 2026
Via ACCESS Newswire
American Science Suffers as Brain Drain Intensifies
February 24, 2026
Via Investor Brand Network

Frequently Asked Questions

Is CNS Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, CNS Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does CNS Pharmaceuticals, Inc. - Common Stock trade on?
CNS Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for CNS Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for CNS Pharmaceuticals, Inc. - Common Stock is CNSP on the Nasdaq Stock Market
What is the current price of CNS Pharmaceuticals, Inc. - Common Stock?
The current price of CNS Pharmaceuticals, Inc. - Common Stock is 6.900
When was CNS Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of CNS Pharmaceuticals, Inc. - Common Stock was at 05/06/26 04:00 PM ET
What is the market capitalization of CNS Pharmaceuticals, Inc. - Common Stock?
The market capitalization of CNS Pharmaceuticals, Inc. - Common Stock is 4.28M
How many shares of CNS Pharmaceuticals, Inc. - Common Stock are outstanding?
CNS Pharmaceuticals, Inc. - Common Stock has 4M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap